

1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof related to said disease state; and  
means for determining binding between said biochemical material and said biomolecule;  
whereby at least one analysis to determine a presence of a marker, analyte thereof, or a  
biochemical material specific thereto, is carried out on a sample.

Claim 29. Polyclonal antibodies produced against a marker sequence ID selected from the  
group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof  
in at least one animal host.

Claim 30. An antibody that specifically binds a biopolymer including a marker selected  
from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 or at least one  
analyte thereof.

Claim 33. A process for identifying therapeutic avenues related to a disease state  
comprising:

conducting an analysis as provided by the kit of claim 18; and  
interacting with a biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID  
NO: 2, SEQ ID NO: 3 or at least one analyte thereof;  
whereby therapeutic avenues are developed.

Claim 34. The process for identifying therapeutic avenues related to a disease state in  
accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the